Clinical Trials Logo

Recurrent Pregnancy Loss clinical trials

View clinical trials related to Recurrent Pregnancy Loss.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05802784 Completed - Subfertility Clinical Trials

Hysteroscopic Septoplasty by Different Modalities

Start date: June 16, 2020
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare in participant population ( women with uterine septum meeting the inclusion criteria) hysteroscopic septoplasty by resectoscope compared to hysteroscopic septoplasty with scissors. The main questions to answer are: Is there a difference in operative time ? Is there a difference in fluid used and fluid deficit? Is there a difference in complications? Is there a difference in reproductive outcome? Researchers will compare the 2 different techniques to see if there is any difference in operative outcome ( operative time, fluid used and deficit, need for second intervention, and operative and postoperative complications) and reproductive outcome.

NCT ID: NCT05342948 Completed - Clinical trials for Recurrent Pregnancy Loss

Association of HY-restricting HLA Class II Alleles, Sex of Firstborn Child, and Pregnancy Outcome in RPL Patients

Start date: January 1, 2016
Phase:
Study type: Observational [Patient Registry]

This cross-sectional and prospective cohort study will investigate if sRPL patients with a first born boy who carry ≥1 HY-restricting (HY-r) HLA class II alleles are associated with a lower chance for a succesful reproductive outcome in first pregnancy after admission compared to sRPL patients with a first born girl carrying ≥1 HY-r HLA class II alleles and women with no HY-r HLA class II alleles and a firstborn boy. Also, the study will compare sRPL patients with a firstborn boy who do not carry a HY-r HLA class II allele with sRPL patients having a firstborn girl and carrying no such alleles. We hypothesize that sRPL patients with a first born boy compared to sRPL patients with a firstborn girl who carry ≥1 HY-r HLA class II alleles is associated with a negative prognosis, while no association between sex of firstborn child and pregnancy outcome is expected in sRPL carrying no HY-r HLA class II alleles. Neither do we expect an association between pregnancy outcome and carriage of HY-r HLA class II alleles in pRPL patients.

NCT ID: NCT05205044 Completed - Clinical trials for Recurrent Pregnancy Loss

Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Start date: January 23, 2022
Phase:
Study type: Observational

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

NCT ID: NCT05073978 Completed - Preterm Birth Clinical Trials

B-vitamin Levels and Adverse Pregnancy Outcomes

Start date: December 1, 2020
Phase:
Study type: Observational

This prospective nested case-control study aims to examine the effects of blood vitamin B levels in first-trimester pregnant women on the pregnancy outcomes

NCT ID: NCT04718233 Completed - Clinical trials for Recurrent Pregnancy Loss

Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss

Start date: September 5, 2018
Phase: Phase 2
Study type: Interventional

Patients with recurrent pregnancy loss are known to have decreased uterine artery blood flow. Nitric oxide plays a major role in increasing uterine blood flow during the luteal phase. This study is done to evaluate the effects of sildenafil on blood flow indices in the patients with recurrent pregnancy loss due to impaired uterine artery blood flow.

NCT ID: NCT04455256 Completed - Clinical trials for Recurrent Pregnancy Loss

Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss

Start date: March 20, 2020
Phase:
Study type: Observational

To evaluate endoplasmic reticulum stress in women with recurrent pregnancy loss and those who had healthy births in the same age group. The level of the unfolded protein X box binding protein 1 (XBP-1) is measured. It is aimed to show the effect of endoplasmic reticulum stress on recurrent pregnancy loss.

NCT ID: NCT04017754 Completed - Clinical trials for Pregnancy Complications

Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)

Start date: January 1, 2016
Phase:
Study type: Observational

The present study is based on the hypothesis, that recurrent pregnancy loss (RPL) is associated with abnormal plasma mannose binding lectin (p-MBL) level. Secondarily, p-MBL level may affect the reproductive and the perinatal outcome in the first pregnancy following RPL. Thus, the present study aim to examine whether MBL should be a biomarker for women at risk for RPL and, secondarily, affect the reproductive and perinatal outcome, and thereby help clinicians identify fragile women who need intensified perinatal care.

NCT ID: NCT03401918 Completed - Clinical trials for Recurrent Pregnancy Loss

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo implantation. Furthermore we would like to assess for women with an abnormal uterine gene expression whether vaginal progesterone medication improves or alters gene expression and for women with an abnormal microbiome whether antibiotic treatment followed by probiotic treatment normalizes the microbiome.

NCT ID: NCT03178682 Completed - Clinical trials for Recurrent Pregnancy Loss

Ultrasound Predictors of Early Pregnancy Failure in Patients With Recurrent Pregnancy Loss

Start date: January 1, 2017
Phase: N/A
Study type: Observational

evaluation of the role of ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss

NCT ID: NCT03174951 Completed - Clinical trials for Recurrent Pregnancy Loss

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

Start date: September 20, 2016
Phase: Phase 2
Study type: Interventional

Miscarriage occurs in about 1-2% of human pregnancies and is one of the common pregnancy problems before 12 weeks of pregnancy. Anatomical and chromosomal abnormalities, microbial factors and auto and alloimmune reactions have been speculated to attribute in recurrent miscarriage. Unexplained recurrent miscarriage (URM) is defined as three or more repeated abortions, probably caused by maternal immunological rejection . Given that maternal immune system encounters semi-allogeneic fetus, pregnancy outcome is associated with the interaction between maternal immune system and immuno-regulatory capability of the fetus. Effectiveness of treatment approaches in RM patients has been controversial and remained to be discovered. Immunomodulatory agents such as corticosteroids and allogeneic lymphocyte immunization showed variable success rates in RM patients. Therapeutic effects of IVIG in unexplained RM is controversial and most positive results were obtained from the trials in RM women with cellular immune abnormalities, such as increased NK cell level and/or cytotoxicity, and T cell abnormalities. Previous studies have shown that the incidence of genetic abnormalities in children who have received immunosuppressive drugs such as IVIg like normal people and normal society. In this study we used IVIg at the time of positive pregnancy,400 mg/kg IVIG was administered intravenously. Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation to suppress the immune system in patients with immunological causes of RPL and the results will be compared with a control group that did not receive any type of drug.